Nonallergic Rhinitis: Developing Drug Products for Treatment

Issue Date: September 6, 2018
Issued by: Center for Drug Evaluation and Research
Topic(s): Clinical – Medical, Pediatric Product Development
Status: Final

Nonallergic Rhinitis: Developing Drug Products for Treatment

The purpose of this guidance is to assist applicants of new drug applications and biologics license applications in developing drug products for the treatment of nonallergic rhinitis (NAR) in children and adults. The guidance discusses issues regarding the definition of a clinical phenotype, trial design, efficacy, and safety for new drug products under development. In particular, the guidance addresses development programs for the treatment of vasomotor rhinitis (VMR), which is a subtype of NAR.

Download the Guidance Document

webmaster2026-08-05T18:58:12+00:00

ABOUT US

Avance Biosciences is a leading Contract Research Organization (CRO) and Contract Testing Organization (CTO) providing CGMP and GLP-compliant analytical and bioanalytical services to support drug development. From early discovery through clinical development and commercialization, we provide CGMP and GLP-compliant services tailored to your therapeutic modality and regulatory needs.